U-95666E: A potential anti-parkinsonian drug with anxiolytic activity

@article{Sethy1997U95666EAP,
  title={U-95666E: A potential anti-parkinsonian drug with anxiolytic activity},
  author={Vimala H. Sethy and Brenda R. Ellerbrock and Haiyan Wu},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={1997},
  volume={21},
  pages={873-883}
}
Central Mechanisms Regulating Penile Erection in Conscious Rats: The Dopaminergic Systems Related to the Proerectile Effect of Apomorphine
TLDR
The results suggest that the proerectile action of apomorphine in rats is mediated at supraspinal levels and that this effect is not mimicked by a D2 receptor agonist but associated with activation of D4 receptors.
The Effects of a Selective Dopamine D2 Receptor Agonist on Behavioral and Pathological Outcome in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Squirrel Monkeys
TLDR
Results suggest that sumanirole can exert antiparkinsonian effects similar to l-DOPA without the behavioral and morphological consequences of the latter.
Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.
TLDR
The ability of ABT-724 to facilitate penile erection together with the favorable side-effect profile indicates that ABT -724 could be useful for the treatment of erectile dysfunction.
Neurotoxic Effects of Methamphetamine
TLDR
Results showed that methamphetamine caused significant generation of reactive oxygen species and decreased complex I activity in the mitochondria leading to dopamine depletion in the striatum in Parkinson’s disease.
Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
TLDR
An overview and update of the major aspects of research related to D3Rs: distribution in the CNS and periphery, signaling and molecular properties, the status of ligands available for D3R research (agonists, antagonists and partial agonists), behavioral functions of D2Rs, the role in neural networks, and a summary on how the D2R-related drug research has been translated to human therapy are provided.
Therapeutic and Diagnostic Agents for Parkinson’s Disease
TLDR
This chapter considers the biology and medical chemistry-based treatment of Parkinson’s disease, the second most common of the major neurodegenerative neuropsychiatric disorders, and future directions of efforts to improve the treatment are considered, with an emphasis on the continued central importance of medicinal chemistry.
Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists
TLDR
A novel class of highly potent Go-protein biased full D2R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin are identified.
Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism.
TLDR
It is found that substitutions in the N-1- and/or N-5-positions, physiochemical properties of those substituents, and secondary aromatic pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
Role of cGMP in the mechanism of anxiolytic activity of U-78875
Zolpidem, a novel nonbenzodiazepine hypnotic. II. Effects on cerebellar cyclic GMP levels and cerebral monoamines.
TLDR
Zolpidem diminished the levels of cerebellar cGMP in the rat markedly and potentiated the diminution of the cyclic nucleotide levels induced by the gamma-aminobutyric acid mimetic, and prevented the increase in 3,4-dihydroxyphenylacetic acid levels in the frontal cortex induced by electric footshock stress.
Regulation of striatal acetylcholine concentration by dopamine receptors
TLDR
Observations suggest that the response to central cholinergic stimulation depends on the functional activity of inhibitory dopamine receptors in the striatum, and the effect of dopamine receptor agonists and antagonists on striatal acetylcholine concentration is tested.
The rationale for the use of dopamine agonists in Parkinson's disease
TLDR
The production of dyskinesias in Parkinson's disease might reflect an imbalance in the D1-direct and D2-indirect GABAergic output pathways from the caudate-putamen, which colocalize tachykinins and enkephalins, respectively, and levodopa treatment leads to a new imbalance between output from the striatum through the direct and indirect pathways.
Regulation of brain acetylcholine concentration by muscarinic receptors.
TLDR
The results indicate that the muscarinic receptor system involved in the regulation of brain Ach levels may lack spare receptors.
Dopamine agonists in Parkinson's disease
TLDR
Dopamine precursors are considered to provide the best symptomatic treatment, whereas dopamine agonists, although less effective, might be important in slowing the progression of the disease.
...
1
2
3
...